Promega Expands Forensic Portfolio with Distribution Agreement for NimaGen’s IDseek® MPS Library Prep Kits
14.4.2026 13:01:00 CEST | Business Wire | Press release
Agreement adds STR, SNP, microhaplotype and mitochondrial DNA MPS kits to Promega forensic product lineup
Forensic casework laboratories will now have access to NimaGen’s IDseek® massively parallel sequencing (MPS) kit portfolio through Promega Corporation, following a distribution agreement announced today between the two companies. The IDseek® line is powered by NimaGen’s patented Reverse Complement PCR (RC-PCR) technology to deliver the sensitivity and specificity required for challenging casework samples. These sequencing kits extend the existing Promega portfolio of sample preparation and capillary electrophoresis (CE)-based STR analysis tools.
“For decades, we have anticipated and responded to the technologies that forensic laboratories need to produce reliable results,” says Tim Kupferschmid, Senior Director of Genetic Identity at Promega. “With this agreement, labs that have long benefited from Promega reagents, instrumentation and support can continue relying on us as they expand their workflows with massively parallel sequencing.”
IDseek® Massively Parallel Sequencing (MPS) Kits
All IDseek® library prep kits are built on RC-PCR technology, which enables forensic MPS library preparation in a single closed-tube reaction. The workflow is designed for the sensitivity demands of forensic casework, including degraded and low-quantity samples, and produces high on-target read yields that maximize sequencing efficiency.
“This marks an important milestone in our growth, extending our sales reach and deepening our technical capabilities to better serve customers around the world,” says Pieter van Oers, Senior Manager of Business Development – Forensics at NimaGen. “Our RC-PCR library preparation technology fundamentally simplifies the MPS workflow, eliminating the complexity that has prevented many laboratories from transitioning to MPS. With our IDseek® MPS library prep portfolio, forensic scientists can now access the power of MPS with a workflow that resembles traditional CE methods, while increasing sample safety, sensitivity and discrimination power of forensic STR testing.”
Under the new agreement, Promega will distribute more than 20 products across seven product families. Examples of applications supported include:
- Autosomal STR profiling (IDseek® OmniSTR™)
- Y-chromosomal STR profiling (IDseek® mYSTR™)
- Autosomal and Y-chromosomal STR profiling (IDseek® CombiSTR™ Plus)
- Microhaplotype analysis (IDseek® OmniHAP™)
- Identity informative SNP typing (IDseek® OmniSNP™)
- Mitochondrial DNA sequencing (IDseek® Mitochondrial HVR and Full Genome kits)
Promega Support for Forensic Laboratories
Promega has supported forensic laboratories for more than 30 years with products, instrumentation and technical expertise spanning the full workflow of human identification. For forensic laboratories evaluating the transition to MPS-based workflows, the ability to access NimaGen’s IDseek® portfolio through an established Promega relationship simplifies the path to MPS adoption. The Promega global distribution network, forensic-specific technical support infrastructure and decades of experience serving casework laboratories mean that laboratories can move into MPS with the same supplier accountability they already rely on for their CE-based workflows.
To learn more about IDseek® products distributed by Promega, click here
About Promega Corporation
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s portfolio of over 4,000 products supports a range of life science work across areas such as cell biology; DNA, RNA and protein analysis; drug development; human identification and molecular diagnostics. These tools and technologies have grown in their application over the last 45 years and are used today by scientists and technicians in labs for academic and government research, forensics, pharmaceuticals, clinical diagnostics and veterinary, agricultural and environmental testing. Promega is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. Learn more at promega.com
About NimaGen
NimaGen B.V. is a biotechnology company specializing in innovative DNA sequencing technologies for forensic applications and human identification. Headquartered in Nijmegen, The Netherlands, NimaGen holds the exclusive license for the patented Reverse Complement PCR (RC-PCR) technology, granted by the Salisbury NHS Foundation Trust, United Kingdom. The company's IDseek® product line represents the next revolution in forensic MPS, combining unmatched sensitivity, robustness, and sample safety with simplified workflows that make advanced sequencing accessible to forensic laboratories worldwide. NimaGen is part of Biolegio Holding.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260413426143/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Webcast Fireside Chat at Barclays Global Consumer Conference on Sept. 1018.8.2026 22:15:00 CEST | Press release
IFF (NYSE: IFF) today announced that Chief Executive Officer Erik Fyrwald will participate in a fireside chat at the Barclays Global Consumer Conference on Thursday, Sept. 10, 2026 at 945 a.m. ET. Investors may access the live webcast on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, and health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818490253/en/
Lehman Brothers Treasury Announces the Successful Sale of its Remaining Intercompany Claim against Lehman Brothers Holdings Inc.18.8.2026 21:15:00 CEST | Press release
In connection with its previously announced final wind-down, Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”), through its U.S. counsel Herbert Smith Freehills Kramer (US) LLP, announced that its placement agent, Seaport Loan Products LLC, successfully closed the sale of LBT’s remaining $19.6 billion Class 4A intercompany claim against Lehman Brothers Holdings Inc. The net proceeds of the sale, together with certain available cash (but after deducting various sale-related and other administrative costs and expenses), will be used to fund a final distribution to the holders of LBT’s existing notes, after which such existing notes will be canceled and LBT shall be fully wound down. As a result, LBT will cease to exist. LBT expects the final distribution to occur in the course of October 2026 and the wind down to have been completed before the end of 2026. View source version on businesswire.com: https://www.businesswire.com/news/home/20260818004215/en/
GenBio AI Builds First World Model of the Human Cell18.8.2026 15:00:00 CEST | Press release
First-of-its-kind system simulates human cell behavior across the full biological hierarchy, from DNA and RNA through protein to the whole-cell level GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions. Today, the company introduced AIDO Cell, its virtual cell world model — the first system capable of simulating a human cell, both in its natural state and in response to drugs and other interventions, across its full biological hierarchy, from DNA and RNA through protein to the whole-cell level. A Key First in Biological and Medical Sciences: Full-hierarchy virtual cell simulation has been widely identified as a key milestone in computational biology. Compared to the previous efforts by
Xsolla Partner Network Expands Verified Creator Partnerships and Unifies Campaign Management Ahead of gamescom 202618.8.2026 15:00:00 CEST | Press release
Developers Gain Vetted Creator Partnerships And A Single Campaign Workflow, Managed From The Publisher Account They Already Use Xsolla, a global video game commerce company, today announced an expansion of the Xsolla Partner Network ahead of gamescom 2026 in Cologne, giving game developers a simpler, more reliable way to grow their games through creators. The creator platform now lives within Xsolla Publisher Account, where developers already run their business, with verified creator onboarding and a redesigned and unified campaign workflow. Flat-fee campaigns, a new guaranteed payment option alongside revenue share, and data-driven creator recommendations are coming soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818140062/en/ Graphic: Xsolla Xsolla Partner Network gives developers one place to launch, manage, track, and report on creator campaigns while Xsolla handles payments, payouts, taxes, and compliance.Verifi
KOCCA to Showcase 13 Korean Game Companies at ‘Gamescom 2026’ with PC, Mobile, and VR Lineups18.8.2026 14:48:00 CEST | Press release
- Featuring a diverse lineup of roguelike deckbuilders, AI-powered rhythm education, and cooperative horror games - Ranging from new titles based on the popular animated IP ‘LARVA’ to real-time K-POP dance coaching content - Hands-on experience available August 26–28 at the Korea Joint Pavilion B2B Hall, Koelnmesse, Booth Hall 3.2 C-050g–D051g The Korea Creative Content Agency (KOCCA) announced that 13 Korean game companies will gather under one roof at Gamescom 2026, Europe’s largest game show, held in Cologne, Germany, from August 26 to 28 (B2B, 09:00~20:00). Located in Booth Hall 3.2 C-050g–D051g, the Korea Joint Pavilion offers visitors hands-on experiences with an expansive lineup of titles, ranging from PC and mobile games to VR-powered titles across diverse genres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260818271881/en/ KOCCA will bring 13 Korean game companies to Gamescom 2026 in Cologne, Germany (Image: KOCC
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom